PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 226-250 of 369

  • PI3Kδ-IN-27
    Cat. No.
    A53516

    PI3Kδ-IN-27

    PI3Kδ-IN-27 is a selective inhibitor of PI3Kδ, exhibiting an IC50 value of 355.3 nM. This compound demonstrates notable antiviral activity against SARS-CoV-2, making it a valuable tool for studying viral infections, particularly COVID-19. Researchers can utilize PI3Kδ-IN-27 to explore pathways related to immune response and infection mechanisms.

    Out of stock

    All 3 sizes
  • ETP-45658
    Cat. No.
    A54588

    ETP-45658

    ETP-45658 is a potent inhibitor of the phosphoinositide 3-kinase (PI3K) family, exhibiting IC50 values of 22.0 nM for PI3Kα, 39.8 nM for PI3Kδ, 129.0 nM for PI3Kβ, and 717.3 nM for PI3Kγ. Additionally, ETP-45658 demonstrates inhibitory effects on DNA-PK (IC50 = 70.6 nM) and mTOR (IC50 = 152.0 nM). This compound is valuable for cancer research, particularly in exploring the roles of PI3K signaling pathways in tumorigenesis and treatment resistance.

    1 mg
    $40.00
    5 mg
    $95.00
    All 6 sizes
  • MEK/PI3K-IN-2
    Cat. No.
    A56875

    MEK/PI3K-IN-2

    MEK/PI3K-IN-2 is a potent inhibitor targeting both MEK and PI3K pathways, exhibiting IC50 values of 352 nM for MEK1, 107 nM for PI3Kα, and 137 nM for PI3Kδ. This compound effectively reduces levels of phosphorylated AKT and ERK1/2, demonstrating significant anti-proliferative activity against various tumor cell lines. MEK/PI3K-IN-2 is valuable for research in cancer biology and therapeutic development aimed at disrupting these critical signaling pathways.

    Out of stock

    All 3 sizes
  • MEK/PI3K-IN-1
    Cat. No.
    A56878

    MEK/PI3K-IN-1

    MEK/PI3K-IN-1 is a potent inhibitor targeting MEK and PI3K pathways, exhibiting IC50 values of 124 nM for MEK1, 130 nM for PI3Kα, and 236 nM for PI3Kδ. This compound effectively reduces levels of phosphorylated AKT (pAKT) and ERK1/2 (pERK1/2), demonstrating significant anti-proliferative effects in various tumor cell lines. MEK/PI3K-IN-1 serves as a valuable tool for research in cancer therapeutics and signaling pathway analysis.

    Out of stock

    All 3 sizes
  • LAS195319
    Cat. No.
    A60431

    LAS195319

    LAS195319 is a potent and orally active inhibitor of PI3Kδ, exhibiting an IC50 of 0.5 nM. This compound demonstrates high selectivity against a wide array of proteins, lipid kinases, and GPCRs. LAS195319 effectively inhibits the infiltration of neutrophils and eosinophils, making it a valuable tool for research into respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD).

    25 mg
    $2,160.00
    50 mg
    $2,770.00
    All 3 sizes
  • VVD-442
    Cat. No.
    A63562

    VVD-442

    VVD-442 is a selective inhibitor of PI3Kα that covalently binds to cysteine 242 within the RAS-binding domain of the PI3K p110α subunit. This binding induces conformational changes that disrupt the interaction between PI3K p110α and RAS proteins, effectively blocking RAS-mediated activation of PI3K. VVD-442 is applicable in research focusing on RAS-mutant cancers and HER2-overexpressing tumors, providing valuable insights into therapeutic strategies targeting these pathways.

    1 mg
    $415.00
    5 mg
    $1,065.00
    All 4 sizes
  • COX-2/PI3K-IN-2
    Cat. No.
    A64410

    COX-2/PI3K-IN-2

    COX-2/PI3K-IN-2 is a potent inhibitor targeting both COX-2 and PI3K pathways, exhibiting an IC50 value of 2.78 nM for PI3K and a Ki value of 3.02 nM for COX-2. This compound demonstrates significant anti-inflammatory and anti-cancer activities, making it valuable for research in oncology and inflammatory disease studies. Its dual-target mechanism provides insights into the therapeutic potential of modulating these critical pathways.

    Out of stock

    All 3 sizes
  • SH-273
    Cat. No.
    A65624

    SH-273

    SH-273 is a potent dual-function compound that acts as a selective inhibitor of PI3Kγ with an IC50 of 7 nM while also stimulating STING function with an EC50 of 100 nM. This unique profile makes SH-273 a valuable tool for investigating signaling pathways involved in pancreatic cancer. Researchers can utilize SH-273 to explore the therapeutic potential of targeting PI3Kγ and enhancing STING-mediated immune responses in cancer models.

    Out of stock

    All 3 sizes
  • IHMT-PI3Kδ-372
    Cat. No.
    A69814

    IHMT-PI3Kδ-372

    IHMT-PI3Kδ-372 is a highly selective inhibitor of PI3Kδ, exhibiting an IC50 of 14 nM. This compound demonstrates significant selectivity over other class I PI3Ks, with 56 to 83-fold differences, as well as over various protein kinases. IHMT-PI3Kδ-372 is suitable for research applications related to chronic obstructive pulmonary disease (COPD), enabling investigations into therapeutic strategies targeting this pathway.

    1 mg
    $95.00
    2 mg
    $145.00
    All 7 sizes
  • Isopsoralidin
    Cat. No.
    A69908

    Isopsoralidin

    Isopsoralidin is a phosphatidylinositol 3-kinase (PI3K) inhibitor that demonstrates potentially hepatotoxic properties and exhibits inhibitory activity on CYP2D6. This compound plays a significant role in research focused on cell signaling pathways related to cancer and metabolic disorders. Its unique mechanism of action makes it a valuable tool for studying PI3K-related biological processes and evaluating therapeutic approaches involving PI3K modulation.

    5 mg
    $355.00
    10 mg
    $580.00
    All 2 sizes
  • ILK-IN-3
    Cat. No.
    A77620

    ILK-IN-3

    ILK-IN-3 is a potent orally active inhibitor of integrin-linked kinase (ILK), a crucial regulator of cell signaling pathways associated with tumor progression and survival. This compound enhances the anticancer efficacy of Docetaxel in orthotopic LCC6 tumor models, making it a valuable tool for research in cancer therapeutics. Its ability to modulate ILK activity positions ILK-IN-3 as a significant molecule for studying cancer biology and potential treatment strategies.

    1 mg
    $25.00
    5 mg
    $50.00
    All 6 sizes
  • ILK-IN-4
    Cat. No.
    A77631

    ILK-IN-4

    ILK-IN-4 is a selective integrin-linked kinase (ILK) inhibitor that disrupts ILK-mediated signaling pathways. It demonstrates potent anti-proliferative activity in various cancer cell lines. This compound is primarily utilized in cancer research to investigate the role of ILK in tumor progression and metastasis.

    Out of stock

    All 3 sizes
  • PKI-179
    Cat. No.
    A79698

    PKI-179

    PKI-179 is a highly effective dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ, and mTOR, respectively. It demonstrates significant activity against E545K and H1047R mutant isoforms, with IC50 values of 14 nM and 11 nM. PKI-179 is utilized in cancer research due to its proven anti-tumor efficacy in vivo, making it a valuable tool for investigating the PI3K/mTOR signaling pathway in various cancer models.

    5 mg
    $205.00
    10 mg
    $335.00
    All 5 sizes
  • PI3K/mTOR Inhibitor-4
    Cat. No.
    A79701

    PI3K/mTOR Inhibitor-4

    PI3K/mTOR Inhibitor-4 is a potent orally active pan-class I PI3K/mTOR inhibitor. It demonstrates enzymatic inhibition across PI3Kα, PI3Kγ, PI3Kδ, and mTOR with IC50 values of 0.63 nM, 22 nM, 9.2 nM, and 13.85 nM, respectively. This reagent is primarily utilized in cancer research to investigate the role of the PI3K/mTOR signaling pathway in tumorigenesis and therapeutic responses.

    2 mg
    $75.00
    5 mg
    $125.00
    All 6 sizes
  • PI3K/mTOR Inhibitor-11
    Cat. No.
    A79703

    PI3K/mTOR Inhibitor-11

    PI3K/mTOR Inhibitor-11 is a potent oral inhibitor of the PI3K/mTOR signaling pathway, exhibiting IC50 values of 3.5 nM, 4.6 nM, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR, respectively. This compound effectively impairs the phosphorylation of AKT and S6 proteins, thereby modulating critical cellular processes. PI3K/mTOR Inhibitor-11 is valuable for cancer research, offering insights into therapeutic strategies targeting aberrant signaling in tumors.

    5 mg
    $445.00
    10 mg
    $715.00
    All 5 sizes
  • DS-7423
    Cat. No.
    A79710

    DS-7423

    DS-7423 is a potent dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 15.6 nM for PI3Kα and 34.9 nM for mTOR. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research into cancer biology and potential therapeutic strategies. Its ability to inhibit key signaling pathways involved in cell growth and survival positions DS-7423 as a promising candidate for further exploration in oncology studies.

    1 mg
    $95.00
    5 mg
    $245.00
    All 6 sizes
  • PI3K-IN-37
    Cat. No.
    A79712

    PI3K-IN-37

    PI3K-IN-37 is a potent inhibitor of the PI3K family, specifically targeting PI3K α, β, and δ isoforms with IC50 values of 6, 8, and 4 nM, respectively. Additionally, PI3K-IN-37 demonstrates strong inhibition of mTOR with an IC50 of 4 nM. This compound is valuable for research applications involving cancer biology, metabolic disorders, and signaling pathways related to cell growth and survival.

    1 mg
    $290.00
    5 mg
    $885.00
    All 5 sizes
  • PI3K-IN-22
    Cat. No.
    A79713

    PI3K-IN-22

    PI3K-IN-22 is a potent dual inhibitor of the PI3Kα and mTOR kinases, with IC50 values of 0.9 nM and 0.6 nM, respectively. This compound exhibits substantial biological activity, making it valuable for investigating the roles of these pathways in cancer research. PI3K-IN-22 can facilitate the study of tumor growth and response to therapy, contributing to the understanding of oncogenic signaling and potential treatment strategies.

    1 mg
    $195.00
    5 mg
    $1,790.00
    All 4 sizes
  • PKI-179 hydrochloride
    Cat. No.
    A79714

    PKI-179 hydrochloride

    PKI-179 hydrochloride is a potent dual inhibitor of the PI3K and mTOR signaling pathways, demonstrating IC50 values of 8 nM for PI3K-α, 24 nM for PI3K-β, 74 nM for PI3K-γ, 77 nM for PI3K-δ, and 0.42 nM for mTOR. This compound is effective against mutant variants E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 hydrochloride has been shown to exhibit significant anti-tumor activity in vivo, making it a valuable tool for cancer research and therapeutic development targeting PI3K/mTOR pathways.

    5 mg
    $205.00
    10 mg
    $335.00
    All 5 sizes
  • SN32976
    Cat. No.
    A79715

    SN32976

    SN32976 is a potent and selective inhibitor of class I phosphoinositide 3-kinases (PI3K) and mTOR, exhibiting IC50 values of 15.1 nM for PI3Kα, 461 nM for PI3Kβ, 110 nM for PI3Kγ, 134 nM for PI3Kδ, and 194 nM for mTOR. This compound demonstrates significant selectivity against a wide panel of 442 kinases. SN32976 is primarily utilized in cancer research, showcasing notable anticancer activity that makes it a valuable tool for studying PI3K/mTOR pathway modulation.

    1 mg
    $95.00
    5 mg
    $215.00
    All 7 sizes
  • PI3K/mTOR Inhibitor-13 sodium
    Cat. No.
    A79718

    PI3K/mTOR Inhibitor-13 sodium

    PI3K/mTOR Inhibitor-13 sodium is a dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mTOR kinase, demonstrating oral bioavailability. This compound exhibits significant biological activity in the modulation of cellular growth and metabolism, making it a valuable tool in research related to sexual dysfunction, solid tumors, and idiopathic pulmonary fibrosis (IPF). Its dual inhibition profile presents opportunities for therapeutic exploration in various disease contexts.

    5 mg
    $345.00
    10 mg
    $530.00
    All 5 sizes
  • PI3K-IN-18
    Cat. No.
    A79719

    PI3K-IN-18

    PI3K-IN-18 is a potent inhibitor of the PI3K/mTOR signaling pathway, selectively targeting PI3K-α and mTOR with IC50 values of 41 nM and 49 nM, respectively. This compound exhibits significant biological activity by disrupting key signaling processes involved in cell growth and proliferation. PI3K-IN-18 is valuable for research applications focused on cancer biology, metabolism, and therapeutic strategies targeting the PI3K/mTOR axis.

    0.5 mg
    $80.00
    1 mg
    $140.00
    All 4 sizes
  • PI3Kα/mTOR-IN-1
    Cat. No.
    A79722

    PI3Kα/mTOR-IN-1

    PI3Kα/mTOR-IN-1 is a selective dual inhibitor targeting PI3Kα and mTOR, exhibiting an IC50 of 7 nM for PI3Kα in cellular assays. It demonstrates Kis of 10.6 nM and 12.5 nM for mTOR and PI3Kα in cell-free assays, respectively. This compound is instrumental in studies related to cancer biology and signal transduction, making it valuable for research involving the modulation of PI3K/mTOR pathways.

    1 mg
    $315.00
    5 mg
    $635.00
    All 6 sizes
  • PI3K/mTOR Inhibitor-9
    Cat. No.
    A79724

    PI3K/mTOR Inhibitor-9

    PI3K/mTOR Inhibitor-9 is a potent inhibitor targeting both the PI3K and mTOR pathways, exhibiting IC50 values of 38 nM for mTOR (in phospho-S6 cellular assays) and 6.6 μM, 6.6 μM, and 0.8 μM for PI3Kα, PI3Kγ, and PI3Kδ, respectively. This compound demonstrates significant biological activity in modulating cellular growth and metabolism, making it a valuable tool for research on cancer and other diseases characterized by dysregulated PI3K/mTOR signaling. Its application in various cellular models facilitates the exploration of therapeutic strategies in oncology and other fields of biomedical research.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • PI3K/mTOR Inhibitor-5
    Cat. No.
    A79728

    PI3K/mTOR Inhibitor-5

    PI3K/mTOR Inhibitor-5 selectively targets both phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), demonstrating IC50 values of 86.9 nM for PI3K and 14.6 nM for mTOR. This dual inhibition has significant implications for cancer research, as it can effectively impede cell proliferation and survival in tumor cells. PI3K/mTOR Inhibitor-5 is suitable for studies investigating the PI3K/mTOR signaling pathway and its role in various diseases, particularly in the contexts of oncology and metabolic disorders.

    25 mg
    $1,530.00
    50 mg
    $1,950.00
    All 3 sizes

Items 226-250 of 369

Added to your cart

View Cart Checkout

    Loading...